Claims for Patent: 5,456,925

Summary for Patent: 5,456,925

Title:	Pharmaceutical compositions containing furan derivatives
Abstract:	The invention relates to a pharmaceutical composition in solid unit dosage form adapted for oral administration, comprising a salt formed between ranitidine and a complex of bismuth with a carboxylic acid selected from tartaric acid and citric acid together with an alkaline salt. For example the composition is in tablet form and comprises ranitidine bismuth citrate and sodium carbonate. The composition shows improved disintegration and/or dissolution.
Inventor(s):	Smith; Norman R. (London, GB2), Heppenstall; Colin R. (Bishops Stortford, GB2), Douglas; Stephen J. (St. Albans, GB2)
Assignee:	Glaxo Group Limited (Middlesex, GB)
Application Number:	08/215,658
Patent Claims:	1. A pharmaceutical composition in tablet form which weighs from about 400 to about 900 mg, said composition comprising a salt formed between ranitidine and a complex of bismuth with a carboxylic acid selected from the group consisting of tartaric acid and citric acid, mixed with an effective amount of from 2 to 8% w/w of an alkaline salt, wherein the amount of alkaline salt is effective to increase the rate of disintegration and dissolution of said composition after swallowing by a patient, and wherein the alkaline salt is selected from the group consisting of carbonates, bicarbonates, citrates and acetates. 2. A composition according to claim 1, containing from 200 to 800 mg of ranitidine bismuth carboxylate per unit dose. 3. A composition according to claim 1, containing from 50 to 95% w/w of ranitidine bismuth carboxylate. 4. A composition according to claim 1, in which said salt of ranitidine is selected from the group consisting of: N-[2-[[[5-[(dimethylamino)methyl]-2-furanyl]methyl]thio]ethyl]-N'-methyl-2 -nitro-1, 1-ethenediamine 2-hydroxy-1,2,3-propanetricarboxylate bismuth (3.sup.+) complex; and N-[2-[[[5-[(dimethylamino)methyl]-2-furanyl]methyl]thio]ethyl]-N'-methyl-2 -nitro-1, 1-ethenediamine [R-(R*R*)]-2, 3-dihydroxybutanedioate bismuth (3.sup.+) complex. 5. A composition according to claim 1, in which said alkaline salt is selected from the group consisting of alkali metal and alkaline earth metal carbonates and bicarbonates and mixtures thereof. 6. A composition according to claim 1, in which said alkaline salt is selected from the group consisting of sodium carbonate, sodium bicarbonate and mixtures thereof. 7. A composition according to claim 1, in which said ranitidine bismuth carboxylateisN-[2-[[[5-[(dimethylamino)methyl]-2-furanyl]methyl]thio]ethyl ]-N'-methyl-2-nitro-1, 1-ethenediamine 2-hydroxy-1,2,3-propanetricarboxylate bismuth (3.sup.+) complex and said alkaline salt is sodium carbonate. 8. A composition according to claim 1, also containing one or more physiologically acceptable carriers or excipients. 9. A composition according to claim 1 in which said ranitidine bismuth carboxylateisN-[2-[[[5-[(dimethylamino)methyl]-2-furanyl]methyl]thio]ethyl ]-N'-methyl-2-nitro-1, 1-ethenediamine-2-hydroxy-1,2,3-propanetricarboxylate bismuth (3.sup.+) and said alkaline salt is sodium carbonate. 10. A composition according to claim 1 which contains about 5% by weight of the alkaline salt. 11. A composition according to claim 10 which contains about 400 mg of ranitidine bismuth citrate.